The relevance of convection in clinical practice: A critical review of the literature

Hemodialysis International

Volumn 10, Issue SUPPL. 1, 2006, Pages

  Pozzoni, Pietro ^a   Di Filippo, Salvatore ^a   Manzoni, Celestina ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Biocompatibility; Dialysis membranes; Hemodiafiltration; Hemofiltration; High flux hemodialysis

Indexed keywords

BETA 2 MICROGLOBULIN;

ANEMIA; BIOCOMPATIBILITY; CALORIC INTAKE; CLINICAL PRACTICE; CLINICAL TRIAL; HEADACHE; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; KIDNEY FUNCTION; MALNUTRITION; MEMBRANE PERMEABILITY; MORBIDITY; MORTALITY; NAUSEA; NUTRITIONAL STATUS; PROTEIN INTAKE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; VOMITING; WELLBEING;

HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; KIDNEY; MOLECULAR WEIGHT; MORBIDITY; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33144484508     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.01188.x     Document Type: Review

References (40)

1. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2003.
2. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19:108-120.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(Suppl 3):S112-S119.
4. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47:186-192.
5. Locatelli F, Marcelli D, Conte F, et al. For the Registro Lombardo Dialisi e Trapianto. Patient selection affects end-stage renal disease outcome comparisons. Kidney Int. 2000; 57(Suppl 74):S94-S99.
6. Daugirdas JT. Pathophysiology of dialysis hypotension: An update. Am J Kidney Dis. 2001; 38(Suppl 4):S11-S17.
7. Chanard J, Brunois JP, Melin JP, Lavaud S, Toupance O. Long-term results of dialysis therapy with a highly permeable membrane. Artif Organs. 1982; 6:261-266.
8. Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int. 1996; 50:1293-1302.
9. Altieri P, Sorba GB, Bolasco PG, et al. On-line predilution hemofiltration versus ultrapure high-flux hemodialysis: A multicenter prospective study in 23 patients. Sardinian Collaborative Study Group of On-line Hemofiltration. Blood Purif. 1997; 15:169-181.
10. Altieri P, Sorba G, Bolasco P, et al. Second Sardinian Multicentre Study. Predilution haemofiltration - the Second Sardinian Multicentre Study: Comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study. Nephrol Dial Transplant. 2001; 16:1207-1213.
11. Gotch FA, Sargent JA. Hemofiltration: An unnecessarily complex method to achieve hypotonic sodium removal and controlled ultrafiltration. Blood Purif. 1983; 1:9-15.
12. Di Filippo S, Manzoni C, Andrulli S, Tentori F, Locatelli F. Sodium removal during pre-dilution haemofiltration. Nephrol Dial Transplant. 2003; 18(Suppl 7):vii31-vii36.
13. Altieri P, Sorba G, Bolasco P, et al. Sardinian Study Group on Hemofiltration On-line. Comparison between hemofiltration and hemodiafiltration in a long-term prospective cross-over study. J Nephrol. 2004; 17:414-422.
14. Bolasco P, Altieri P, Andrulli S, et al. Convection versus diffusion in dialysis: An Italian prospective multicentre study. Nephrol Dial Transplant. 2003; 18(Suppl 7):50-vii54.
15. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anemia of haemodialysis patients. Nephrol Dial Transplant. 2000; 15:1399-1409.
16. Wizemann V, Lotz C, Techert F, Uthoff S. On-line hemodiafiltration versus low-flux haemodialysis: A prospective randomized study. Nephrol Dial Transplant. 2000; 15(Suppl 1):S43-S48.
17. Van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int. 1991; 39:1012-1019.
18. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol. 1996; 16:484-488.
19. Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int. 1997; 52:1096-1101.
20. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi e Trapianto. Kidney Int. 1999; 55:286-293.
21. Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrol Dial Transplant. 2000; 16:840-845.
22. Nakai S, Iseki K, Tabei K, et al. Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis. 2001; 38(Suppl 1):S212-S216.
23. Lindsay RM, Spanner E. A hypothesis: The protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis. 1989; 13:382-389.
24. Lindsay RM, Spanner E, Heidenheim P, Kortas C, Blake PG. PCR, Kt/V and membrane. Kidney Int. 1993; 43(Suppl 41):S268-S273.
25. Kobayashi H, Ono T, Yamamoto N, et al. Removal of high molecular weight substances with large pore size membrane (BK-F). Kidney Dial. 1993; 34(Suppl 1):154-157.
26. Villaverde M, Perez-Garcia R, Verde E, et al. La polisulfona de alta permeabilidad mejora la respuesta de la anemia a la eritropoyetina en hemodialisis. Nefrologia. 1999; 19:161-167.
27. Kawano J, Takaue Y, Kuroda Y, et al. Effect on alleviation of renal anemia by hemodialysis using the high-flux dialyzer (BK-F). Kidney Dial. 1994;200-203.
28. Maduell F, Del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant. 1999; 14:1202-1207.
29. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line prepared substitution fluid. Blood Purif. 2002; 20:357-363.
30. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000; 15:1207-1211.
31. Caramelo C, Alcazar R, Gallar P, et al. Chioice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant. 1994; 9:675-677.
32. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF. The effect of membrane biocompatibility on plasma β2-microglobulin levels in chronic haemodialysis patients. J Am Soc Nephrol. 1996; 7:472-478.
33. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis. 1997; 30:366-373.
34. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002; 61:256-265.
35. Hornberger JC, Chernew M, Petersen J, Garber AM. A multi-variate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol. 1992; 3:1227-1237.
36. Leypoldt JK, Cheung AK, Carroll CE, et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis. 1999; 33:349-355.
37. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant. 2000; 15(Suppl 1):S36-S42.
38. Port FK, Wolfe RA, Hulbert-Shearon TE, et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis. 2001; 37:276-286.
39. Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347:2010-2019.
40. Locatelli F, Hannedouche T, Jacobson S, et al. The effect of membrane permeability on ESRD: Design of a prospective randomised multicentre trial. J Nephrol. 1999; 12:85-88.